Richard A. Walsh – författare

Part of the "What Do I Do Now?" series, Movement Disorders uses a case-based approach to cover common and important topics in the examination, investigation, and management of Parkinson's disease, gait disorders, dystonia, and other movement disorders. Each chapter provides a discussion of the diagnosis, key points to remember, and selected references for further reading. For this edition, all cases and references have been updated and fifteen new cases have been added including: Genetic testing in Parkinson's disease, Dementia with Lewy Bodies, Fragile X Tremor Ataxia Syndrome, Botulinum Toxin, Catatonia, and Serotonin Syndrome. Movement Disorders is an engaging collection of thought-provoking cases which clinicians can utilize when they encounter difficult patients. The volume is also a self-assessment tool that tests the reader's ability to answer the question, "What do I do now?"

Part of the "What Do I Do Now?" series, Movement Disorders uses a case-based approach to cover common and important topics in the examination, investigation, and management of Parkinson''s disease, gait disorders, dystonia, and other movement disorders. Each chapter provides a discussion of the diagnosis, key points to remember, and selected references for further reading. For this edition, all cases and references have been updated and fifteen new cases have been added including: Genetic testing in Parkinson''s disease, Dementia with Lewy Bodies, Fragile X Tremor Ataxia Syndrome, Botulinum Toxin, Catatonia, and Serotonin Syndrome. Movement Disorders is an engaging collection of thought-provoking cases which clinicians can utilize when they encounter difficult patients. The volume is also a self-assessment tool that tests the reader''s ability to answer the question, "What do I do now?"

Part of the "What Do I Do Now?" series, Movement Disorders uses a case-based approach to cover common and important topics in the examination, investigation, and management of Parkinson''s disease, gait disorders, dystonia, and other movement disorders. Each chapter provides a discussion of the diagnosis, key points to remember, and selected references for further reading. For this edition, all cases and references have been updated and fifteen new cases have been added including: Genetic testing in Parkinson''s disease, Dementia with Lewy Bodies, Fragile X Tremor Ataxia Syndrome, Botulinum Toxin, Catatonia, and Serotonin Syndrome. Movement Disorders is an engaging collection of thought-provoking cases which clinicians can utilize when they encounter difficult patients. The volume is also a self-assessment tool that tests the reader''s ability to answer the question, "What do I do now?"

Patients suffering from movement disorders pose many challenges for the clinician, and even the most experienced of practitioners can arrive at the point where diagnostic, work-up, treatment, or prognostic thinking falters.Authored by three leading experts in the field, Movement Disorders walks the reader through the important principles of examination, investigation, and management for each of the common types of movement disorders. Applying a case-based approach, each chapter in this volume of the "What Do I Do Now?" series in neurology presents the reader with a real-time patient encounter, detailing the thinking behind diagnostic and treatment decision-making. Some of the presentations featured in Movement Disorders are quite rare, offering the clinician a quick reference tool for those difficult clinical situations. Succinct and direct, Movement Disorders is the perfect guide to answering the common, and uncommon, questions in this subspecialty of neurology.

This title reviews current knowledge of the mechanisms contributing to heart failure. Editor Richard Walsh and an internationally renowned team of contributors discuss key advances in molecular and cell biology, biochemistry, and pharmacology, focusing on advances that have a direct bearing on current clinical studies. It highlights developments across a broad range of disciplines, with in-depth coverage of each topic providing background and perspective on current literature. By setting new advances in a broader context, this text allows readers to compare different ideas and evaluate their importance in their own areas of research or clinical practice.

This title reviews current knowledge of the mechanisms contributing to heart failure. Editor Richard Walsh and an internationally renowned team of contributors discuss key advances in molecular and cell biology, biochemistry, and pharmacology, focusing on advances that have a direct bearing on current clinical studies. It highlights developments across a broad range of disciplines, with in-depth coverage of each topic providing background and perspective on current literature. By setting new advances in a broader context, this text allows readers to compare different ideas and evaluate their importance in their own areas of research or clinical practice.

The advances in molecular biology and genetics coupled with the progress in instrumentation and surgical techniques have produced a voluminous and often bewildering quantity of data. The primary objective of this second edition is to critically interpret the literature and to provide a framework for the enormous amount of information in this burgeoning field. As in the first edition, the monograph serves as a practical guide for the investigator interested in the functional methods used to characterize the murine cardiovascular phenotype. The monograph is organized into three parts. The first deals with principles of transgenesis and homologous recombination. The second part, which again is the largest, discusses the various techniques used to assess the cardiovascular mechanical, metabolic, and electrophysiologic phenotype. This section is organized in a hierarchical manner - i.e. from isolated myocyte to isolated heart to the intact, anesthetized and conscious mouse.The third part examines techniques used to evaluate murine smooth muscle function, genetic mouse models of hypertrophy and heart failure, and the methods to assess the cardiovascular phenotype in the developing mouse embryo. In addition, newer methods that "push the envelope", such as magnetic resonance imaging (MRI), positron emission tomography (PET), ultrasound biomicroscopy (UBM), and computed tomography (microCT) are discussed. Expanded and updated, each chapter is richly enhanced with original tables and figures, and in many cases, extensively rewritten when compared with the first edition. An essential and enduring goal of this second edition is to continue to facilitate interactions between the basic science disciplines and help bridge the gap between molecular biology and physiology.

This title reviews current knowledge of the mechanisms contributing to heart failure. Editor Richard Walsh and an internationally renowned team of contributors discuss key advances in molecular and cell biology, biochemistry, and pharmacology, focusing on advances that have a direct bearing on current clinical studies. It highlights developments across a broad range of disciplines, with in-depth coverage of each topic providing background and perspective on current literature. By setting new advances in a broader context, this text allows readers to compare different ideas and evaluate their importance in their own areas of research or clinical practice.

The enormous advances in molecular biology and genetics coupled with the progress in instrumentation and surgical techniques have produced a voluminous and often bewildering quantity of data. The need for a second edition of Cardiovascular Physiology in the Genetically Engineered Mouse is underscored not only by these rapid advances, but by the increasing numbers of scientists who have focussed their research on genetically engineered mice. It is the primary objective of this second edition to interpret critically the literature and to provide a framework for the enormous amount of information in this burgeoning field. As in the first edition, the monograph serves as a practical guide for the investigator interested in the functional methods used to characterize the murine cardiovascular phenotype. However, this guidebook is a more comprehensive text than its predecessor; although the major objectives enumerated in the first edition have not substantially changed, they have been refined in keeping with the increased sophistication of the molecular biologist, geneticist, and physiologist in each other's discipline. Each chapter has been expanded and updated, richly enhanced with original tables and figures, and in many cases, extensively rewritten. Eight chapters written by internationally recognized experts have been added; this represents a 43 % increase from the first edition.

The enormous advances in molecular biology and genetics coupled with the progress in instrumentation and surgical techniques have produced a voluminous and often bewildering quantity of data. The need for a second edition of Cardiovascular Physiology in the Genetically Engineered Mouse is underscored not only by these rapid advances, but by the increasing numbers of scientists who have focussed their research on genetically engineered mice. It is the primary objective of this second edition to interpret critically the literature and to provide a framework for the enormous amount of information in this burgeoning field. As in the first edition, the monograph serves as a practical guide for the investigator interested in the functional methods used to characterize the murine cardiovascular phenotype. However, this guidebook is a more comprehensive text than its predecessor; although the major objectives enumerated in the first edition have not substantially changed, they have been refined in keeping with the increased sophistication of the molecular biologist, geneticist, and physiologist in each other''s discipline. Each chapter has been expanded and updated, richly enhanced with original tables and figures, and in many cases, extensively rewritten. Eight chapters written by internationally recognized experts have been added; this represents a 43 % increase from the first edition.